Tag: equity
-
Novartis Gains Synthetic Protein Therapies for Covid-19
Global drug maker Novartis is gaining access to two Covid-19 therapy candidates made from a library of synthetic protein components.
-
Bayer Gains Gene Therapy Biotech in $4B Deal
Global drug maker Bayer AG is acquiring the company Asklepios BioPharmaceutical, developer of gene therapies to treat inherited disorders.
-
Start-Up Developing Engineered B-Cell Therapies
A new enterprise, spun off from Seattle Children’s Research Institute, is creating therapeutics for diseases from engineered B-cells in the immune system.
-
Q3 Venture Funds Inch Up, Early-Stage Deals Drop
Venture capital funding rose in the third quarter of 2020, driven in large part by investments in already established companies rather than newer enterprises.
-
Lilly Gains Neuro Disease Biotech in $1.36B Deal
Drug maker Eli Lilly and Co. is acquiring Disarm Therapeutics, a biotechnology company developing treatments for neurodegenerative disorders.
-
New Company IDs Drugs Targeting Cancer Cell Networks
A start-up company is using artificial intelligence to discover drugs that address the tumor stroma, a cellular network supporting cancerous tumors.
-
Microbiome Therapies Company Unveils, Raises $50M
A new enterprise is underway developing therapeutics targeting bacterial communities in the body, to treat metabolic disorders and cancer.
-
Heart Disease Biotech Acquired in $13.1B Deal
A company developing precision medicine drugs to treat inherited heart disorders was acquired by drug maker Bristol Myers Squibb, or BMS, for $13.1 billion.
-
Infographic – Global Climate Technology Hubs
The report also highlights where the investments were made, with the geographic hubs or clusters attracting the most investments, this weekend’s infographic.
-
Chip-Based RNA Biotech Raises $60M in Venture Funds
A company developing messenger RNA therapeutics on demand from single-use biochips is raising $60 million in its second venture funding round.